News Release

Mallinckrodt to Present at Oppenheimer 26th Annual Healthcare Conference

CHESTERFIELD, United Kingdom, Nov. 10, 2015 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Tuesday, Dec. 8, 2015, at the Oppenheimer 26th Annual Healthcare Conference at the Westin Grand Central, 212 E. 42nd St., in New York City. The conference is Dec. 8 and 9. 

Mark Trudeau, President and Chief Executive Officer; Matt Harbaugh, Senior Vice President and Chief Financial Officer; and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a session scheduled from 8:35 a.m. to 9:05 a.m. Eastern Time.

Individuals who cannot attend the meeting in person can find webcast information at: A replay will also be available following the meeting.

Mallinckrodt is a global specialty biopharmaceutical and imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. To learn more about Mallinckrodt, visit


Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Rhonda Sciarra
Senior Manager, Communications

Meredith Fischer
Senior Vice President, Communications and Public Affairs

Logo -


To view the original version on PR Newswire, visit:

SOURCE Mallinckrodt plc